REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/YH/0076	208944	CALM-DIEM_UK â€“ CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHDâ„¢â€“ DEFINING EFFICACY MARKERS	Number Agreed	3	3	Not Available / Not Agreed			23/11/2017	0	withdrawn by sponsor
16/SW/0201	205118	Open-label Phase-4 study to ezamine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2mg aflibercept according to EU label for the first year of treatment	Number Agreed			Not Available / Not Agreed			13/12/2017	0	withdrawn by sponsor
17/LO/1091	229631	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection	Number Agreed	4	4	Not Available / Not Agreed			18/10/2017	0	withdrawn by sponsor
17/EE/0100	215559	A prospective, consecutively enrolling, non-randomized multi centre post-market registry to evaluate the low profile (14F) OvationÂ® Abdominal Stent Graft Platform when used in the endovascular treatment of female patients with abdominal aortic aneurysm	Number Agreed	5	5	Date Agreed	30/04/2018		07/12/2017	0	withdrawn by sponsor
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.	Number Agreed	1	1	Date Agreed	31/10/2017		07/11/2017	1	Recruitment finished
17/LO/0783	225826	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the Efficacy of LUMINITYÂ® and SonoVueÂ® in the Evaluation of Left Ventricular Endocardial Border Definition	Number Agreed	4	4	Date Agreed	14/05/2018		21/03/2018	0	Recruitment finished
16/EM/0099	190876	Prospective, Randomised, Controlled Clinical Trial Designed to Confirm the Efficacy and Safety of the Fotona Smooth Device to Treat Female Stress Urinary Incontinence	Not Available / Not Agreed			Not Available / Not Agreed			19/06/2017	0	withdrawn by sponsor
17/LO/0401	217921	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	Number Agreed	1	1	Date Agreed	09/02/2018		23/06/2017	1	Recruitment finished
16/EM/0220	199415	A randomized parallel group phase III trial of OSE2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)	Not Available / Not Agreed			Not Available / Not Agreed			03/07/2017	0	withdrawn by sponsor
17/LO/0418	220385	A Phase II Multi Centre Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung	Number Agreed	3	3	Not Available / Not Agreed			02/11/2017	0	Withdrawn by Host

17/SC/0130	33635	A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Combination with Exemestane or Fulvestrant Followed by a Parallel Randomized Phase II Study Comparing the Combination of GS-5829 with Exemestane to Exemestane Alone and the Combination of GS-5829 with Fulvestrant to Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive Breast Cancer	Not Available / Not Agreed			Not Available / Not Agreed			06/06/2017	0	Withdrawn by Host
17/LO/0024	212247	An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma	Number Agreed	8	8	Not Available / Not Agreed			26/03/2018	0	withdrawn by sponsor
16/NE/0415	217915	A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir (ODV), with or without Simeprevir (SMV), in Treatment-NaÃ¯ve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C infection with or without compensated Child Pugh A Cirrhosis	Number Agreed	5	5	Date Agreed	30/06/2018		18/10/2017	0	withdrawn by sponsor
16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHNâ€™S DISEASE	Number Agreed	1	2	Date Agreed	31/10/2017		21/12/2017	0	withdrawn by sponsor
16/LO/2038	208640	A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)	Number Agreed	5	5	Date Agreed	31/05/2017		19/04/2017	0	Withdrawn by Sponsor
16/EE/0526	217214	A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStatTM and absorbable haemostatic gelatin sponge in intraoperative surgical haemostasis	Not Available / Not Agreed			Not Available / Not Agreed			07/07/2017	0	Withdrawn by Sponsor
16/EM/0381	212197	A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant	Number Agreed	1	1	Not Available / Not Agreed			12/10/2017	0	Recruitment finished
16/NW/0628	194200	A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.	Number Agreed	2	4	Date Agreed	17/06/2017		23/10/2017	0	withdrawn by sponsor
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction	Number Agreed	8	15	Date Agreed	05/01/2020		29/01/2018	0	Withdrawn by Sponsor
16/WM/0433	215494	A research study to describe the â€œreal worldâ€ use of Thrombopoietin-Receptor Agonists (TRAs) in the management of Immune Thrombocytopenia (ITp) in the UK	Number Agreed	20	20	Date Agreed	31/08/2017		31/08/2017	39	Recruitment finished
17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	3	3	Date Agreed	31/05/2018		22/09/2017	0	withdrawn by sponsor
16/WM/0250	194366	A prospective, multi-national, multicentre, non-interventional study to evaluate the long term safety of Esmya, in particular the endometrial safety, and the current prescription and management patterns of Esmya in a long term treatment setting.	Number Agreed	10	10	Date Agreed	31/03/2018		31/03/2018	4	Withdrawn by Sponsor
16/NW/0728	211957	Investigation of the impact of healthcare professionals advice on the development of good sleep habits in babies under 12 months of age	Not Available / Not Agreed			Not Available / Not Agreed			31/12/2017	0	Recruitment finished
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular Systemâ„¢	Number Agreed	10/01/1900	10/01/1900	Date Agreed	07/07/2021		27/10/2017	5	withdrawn by sponsor

16/EM/0376	211430	The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods	Number Agreed	04/01/1900	04/01/1900	Date Agreed	15/02/2018		15/02/2018	0	Recruitment finished
16/NE/0078	199055	A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B	Not Available / Not Agreed	01/01/1900	01/01/1900	Not Available / Not Agreed			18/05/2017	0	withdrawn by sponsor
16/SS/0134	199690	A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS	Number Agreed	03/01/1900	03/01/1900	Date Agreed	28/02/2019		02/03/2018	0	withdrawn by sponsor
16/EM/0180	199125	A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women	Number Agreed	08/01/1900	08/01/1900	Date Agreed	21/09/2017		23/09/2017	3	Withdrawn by Sponsor
16/EE/0195	200168	A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)	Number Agreed	03/01/1900	03/01/1900	Not Available / Not Agreed			20/06/2017	1	Withdrawn by Sponsor
16/SC/0161	186322	A Phase III, Open-Label, Randomized Study Of Atezolizumab (Mpdl3280a, Anti-Pdâ€‘L1Â Antibody) In Combination With CarboplatinÂ Or CisplatinÂ +Â Pemetrexed Compared With Carboplatin Or CisplatinÂ +Â Pemetrexed In Patients Who Are Chemotherapyâ€‘Naive And Have StageÂ Iv Non-Squamous Non-Small Cell Lung Cancer	Number Agreed	06/01/1900	06/01/1900	Date Agreed	01/07/2017		07/04/2017	4	Recruitment finished
16/YH/0004	190267	A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor	Number Agreed	02/01/1900	02/01/1900	Date Agreed	29/01/2021		07/11/2017	0	Recruitment finished
15/LO/1879	186859	A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib	Number Agreed	04/01/1900	04/01/1900	Date Agreed	15/12/2022		10/05/2017	0	Withdrawn by Sponsor
16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Number Agreed	07/01/1900	07/01/1900	Not Available / Not Agreed			07/02/2018	9	Recruitment finished
15/WA/0358	189344	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of a two-dose regimen of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), in patients with a hematologic malignancy, who received a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor	Number Agreed	02/01/1900	02/01/1900	Date Agreed	10/03/2017		21/11/2017	3	Recruitment finished
16/LO/0014	190759	A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis of Coronary Artery Disease	Number Agreed	10/01/1900	12/01/1900	Date Agreed	10/04/2017		05/04/2017	12	Recruitment finished
13/NE/0005	100377	Product Surveillance Registry â€“ A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market-released products within diabetes, cardiac rhythm disorders, urological, gastrointestinal, spinal, orthopaedic, neurological and ear nose and throat conditions	Number Agreed	07/01/1900	07/01/1900	Date Agreed	28/04/2017		28/04/2017	8	Recruitment finished
15/NW/0431	177346	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	Number Agreed	02/01/1900	02/01/1900	Date Agreed	24/07/2017		06/12/2017	1	Recruitment finished

15/LO/2098	182147	A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome	Number Agreed	14/01/1900	14/01/1900	Date Agreed	01/02/2018		11/12/2017	3	Recruitment finished
15/SC/0303	167788	A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q)	Number Agreed	05/01/1900	05/01/1900		31/12/2019		01/06/2017	0	Withdrawn by Host
16/EM/0259	165592	A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus masitinib alone, versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer	Number Agreed	03/01/1900	03/01/1900	Date Agreed			22/07/2017	3	Recruitment finished
15/WM/0327	185434	Clinical evaluation of the Therapeutic IntraVascular Ultrasound (TIVUSâ„¢) System for pulmonary artery denervation in patients with pulmonary hypertension	Number Agreed	05/01/1900	05/01/1900	Date Agreed	30/06/2017		02/10/2017	2	Recruitment finished
15/NW/1602	173844	A retrospective analysis of tyrosine kinase inhibitor (TKI) efficacy and BCR-ABL mutation status in patients with CML	Number Agreed	15/01/1900	15/01/1900	Date Agreed	31/05/2016		20/06/2017	45	Recruitment finished
15/SC/0409	183061	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration	Number Agreed	10/01/1900	10/01/1900	Date Agreed	03/06/2019		07/04/2017	0	Recruitment finished
15/LO/1105	181406	A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	Number Agreed	03/01/1900	03/01/1900	Date Agreed	19/09/2016		10/04/2017	0	Withdrawn by Sponsor
15/LO/1676	180815	A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen.	Not Available / Not Agreed			Not Available / Not Agreed			21/03/2018	0	Withdrawn by Host
14/NI/0002	143644	AN OPEN LABEL, REGISTRY STUDY OF THE SAFETY OF ILUVIENÂ® 190 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR	Number Agreed	12/01/1900	12/01/1900	Date Agreed	30/12/2016		12/07/2017	12	Recruitment finished
14/YH/1153	159477	An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis (hydromethanesulfonate) in Subjects with Alzheimerâ€™s Disease or Behavioral Variant Frontotemporal Dementia	Number Agreed	10/01/1900	10/01/1900	Not Available / Not Agreed			14/06/2017	14	Recruitment finished
07/H1102/84		Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	Number Agreed	03/01/1900	03/01/1900	Not Available / Not Agreed			30/08/2017	0	Recruitment finished
12/YH/0179	102439	A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia.	Number Agreed	02/01/1900	02/01/1900	Date Agreed	19/11/2013		15/02/2018	2	Recruitment finished